发明名称 HCV polymerase inhibitors
摘要 The invention provides compounds of the formula:; wherein B is a nucleobase selected from the groups (a) to (d): ; and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
申请公布号 US9540411(B2) 申请公布日期 2017.01.10
申请号 US201615210500 申请日期 2016.07.14
申请人 MEDIVIR AB 发明人 Kalayanov Genadiy;Torssell Staffan;Wahling Horst
分类号 C07H19/213;C07H19/11;C07H19/073;C07H19/173 主分类号 C07H19/213
代理机构 Gorman IP Law, APC 代理人 Gorman IP Law, APC
主权项 1. A compound represented by formula: wherein: B is a nucleobase selected from the groups (a) to (d): wherein Y is N or —C(R19)—; R3 is OH, C1-C6alkoxy, C3-C7cycloalkoxy, C3-C7cycloalkylC1-C3alkoxy, benzyloxy, O—(C1-C6alkylene)-T-R21 or NHC(R15)(R15′)C(═O)R16; R4, R5, R7 and R8 are each independently H, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, halo, —OR18, —SR18 or —N(R18)2; R6, R9, R10, R11 are each independently selected from H, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, halo, OR18, SR18, N(R18)2, —NHC(O)OR18, —NHC(O)N(R18)2, —CN, —NO2, —C(O)R18, —C(O)OR18, —C(O)N(R18)2 and —NHC(O)R18, wherein said C2-C6alkenyl group and said C2-C6alkynyl group can be optionally substituted with halo or C3-C5cycloalkyl; R16 is H, C1-C10alkyl, C2-C10alkenyl, C3-C7cycloalkyl, C3-C7cycloalkylC1-C3alkyl, benzyl, phenyl or adamantyl, any of which is optionally substituted with 1, 2 or 3 groups, each independently selected from halo, OR18 and N(R18)2; each R18 is independently H, C1-C6alkyl, C1-C6haloalkyl or C3-C7cycloalkyl; each R21 is independently H, C1-C24alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C7cycloalkyl or C3-C7cycloalkenyl; U is O or S; each T is independently —S—, —O—, —SC(O)—, —C(O)S—, —SC(S)—, —C(S)S—, —OC(O)—, —C(O)O— and —OC(O)O—; or a pharmaceutically acceptable salt and/or solvate thereof.
地址 Huddinge SE